[Evaluation of the clinical effect and tissue distribution of cefpimizole in the field of gynecology].
Cefpimizole (AC-1370) was administered to 5 cases with uterine myoma before hysterectomy, and tissue distribution was determined. AC-1370 was also administered to 5 cases with gynecological infections. The following results were obtained. One gram of AC-1370 was administered from 43 to 299 minutes before hysterectomy, tissue distribution of AC-1370, such as ovary, oviduct, myometrium, cervix uteri, and portio vaginalis was showed the highest level (30.0 approximately 49.5 micrograms/g) at 43 minutes after administration, and these were 39.0 approximately 64.4% of the concentration in uterine arterial blood. Tissue concentration of AC-1370 was then gradually decreased following with the decreasing of the concentration in uterine arterial blood. AC-1370 was administered to 3 cases with pyometra, 1 case with Bartholin abscess, 1 case with adnexitis. The clinical efficacy was good in all 5 cases. Bacteriological study revealed that A. faecalis and E. coli were eradicated, but B. fragilis was persisted. No side effect was observed in all cases.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002511:Cephalosporins / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005836:Genitalia, Female / Q000378:metabolism; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D011247:Pregnancy; D014018:Tissue Distribution
D002511:Cephalosporins; C038845:cefpimizole